HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.
about
Human CD4(+) T-Cells: A Role for Low-Affinity Fc ReceptorsClinical use and applications of histone deacetylase inhibitors in multiple myelomaHDAC inhibitors and immunotherapy; a double edged sword?Regulatory myeloid cells in transplantationHistone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophagesThe role of epigenetic mechanisms and processes in autoimmune disordersDendritic cell-associated miRNAs are modulated via chromatin remodeling in response to different environments.Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protectionExposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cellsIncreased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancerImproving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4Histone/protein deacetylases and T-cell immune responsesInhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.Enhanced B Cell Alloantigen Presentation and Its Epigenetic Dysregulation in Liver Transplant RejectionHDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.Histone deacetylase inhibitors in the generation of the anti-tumour immune response.HDACi: molecular mechanisms and therapeutic implications in the innate immune system.Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.The therapeutic potential of epigenetics in autoimmune diseases.Panobinostat for the treatment of multiple myeloma.Transcriptional and epigenetic networks in the development and maturation of dendritic cells.Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.Novel therapies for cutaneous T-cell lymphoma: what does the future hold?Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Epigenomics of autoimmune diseases.Cinnamamide Derivatives for Central and Peripheral Nervous System Disorders--A Review of Structure-Activity Relationships.Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphomaEpigenetics and innate immunity: the 'unTolld' story.Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients.Involvement of IL-17 in Secondary Brain Injury After a Traumatic Brain Injury in Rats.Modulation of antitumor immunity with histone deacetylase inhibitors.
P2860
Q26745538-A03E55C8-0959-4510-9D5B-7EC1D6456693Q26745930-CC33C8ED-8868-405E-A49F-FCEFA22028A7Q26853102-8ED21612-CB68-4557-AAF8-577F19EE95E7Q26999875-C1255175-3E02-4372-9E5C-03B9AD73B389Q28294510-103E9214-F8D6-473F-90ED-9F03AC8CE649Q28389137-25B5B0A1-3DF2-4D20-BA0A-A12CAF5C8B1DQ31155451-7D5E21C0-86BF-4DE5-8B75-BB359116CB7DQ32945672-1BF6479E-2536-4066-A08D-626A601641ECQ33570005-67EC9335-C23F-42B5-AE86-69FD2D826909Q33928765-C9A076C3-3B37-4A6A-8244-0C0611406AB2Q34935239-380A656C-AD0D-4AC8-85D5-398FBC40561CQ35016934-AEEF5691-43DE-45B2-B4BE-EF8DEA3C70DDQ35556061-4A634DAB-B1C2-4FD1-B41F-4BE64318DB73Q35849307-5ACCE11B-21C1-4F9E-9C5D-97A0991DC47EQ36799721-AAE45200-5C32-421B-8B4A-0A807481C840Q36802272-7A404417-A914-4892-8C84-B55C1D2BE880Q37340304-45ADDD7E-54C9-458D-8F41-EE6EA6A6AF8DQ37370835-6F359E53-D029-4709-8C1E-E05C6EE6AF4CQ37949185-43C82F83-7559-431D-9AAE-4FF2608A992DQ37953826-14D94D91-2BDA-486A-B5D8-D2F1BE4C1A1CQ37956176-24791C3E-1211-4B55-9F28-07DFDABA29CEQ37959304-87B7121E-A19A-4FD3-ADB6-CE1D41749DC5Q37967566-A2D6220D-0127-4E40-BFD7-72CE387BE6EDQ37992104-9DED28E8-F7CA-4CC9-9E11-A5E9890C09F2Q38097109-2224C1A8-8326-42DF-AA64-495D485CF8DAQ38110935-6C21A63B-9B9E-442F-B45F-68221A367DD3Q38159805-6AA4B564-A1DA-4026-8C06-01795BDB0E9CQ38176398-BF1A00DF-556C-4192-95DB-29F9E4CFE8E7Q38240733-84A78027-FF96-4445-8739-20E3D62753D5Q38380209-2DBD7F8B-8A2A-4802-BBBE-64BF8E3947EDQ38530238-50B06163-28BE-41DB-8943-73D1B7FDCA17Q38740003-C993DE8C-52E5-425D-9AB3-2EB1E0E00A05Q38754198-87788872-256D-4165-9A4E-1EFA2ED898E2Q38763747-A66649FD-C709-49C6-8ACE-7F24C7167019Q38950582-A64264D1-4436-4FEA-8B36-8140753CC93BQ39323511-EC9579FA-99FE-469C-8D64-01ED61E2F5A8Q41885967-435CE34C-A1CD-403B-9F1D-1C066D7C1EEEQ43497561-EB4F6AB0-307D-4B7F-8EB3-50D3F5B77A3FQ47793104-9798C576-9446-4028-A719-D69B3C05CF38Q49557954-4882BC30-253D-4F62-9DB9-A7866926A2B8
P2860
HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.
@en
HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.
@nl
type
label
HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.
@en
HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.
@nl
prefLabel
HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.
@en
HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.
@nl
P2093
P2860
P356
P1433
P1476
HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells
@en
P2093
K C Anderson
N C Munshi
P Nanjappa
T Hideshima
P2860
P2888
P304
P356
10.1038/LEU.2010.244
P50
P577
2010-11-19T00:00:00Z